Loading...
XNAS
OVID
Market cap20mUSD
Jun 12, Last price  
0.29USD
1D
-9.25%
1Q
-33.33%
IPO
-97.74%
Name

Ovid Therapeutics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
36.35
EPS
—
Div Yield, %
—
Shrs. gr., 5y
12.57%
Rev. gr., 5y
%
Revenues
566k
+44.50%
00000012,617,221208,382,7791,502,748391,695566,000
Net income
-26m
L-49.50%
-446,892-13,160,093-22,414,352-64,806,054-51,979,610-59,258,017-80,728,728122,834,584-51,408,292-52,338,959-26,433,000
CFO
-56m
L+22.23%
-261,281-5,485,480-17,801,971-31,469,909-45,558,480-51,090,622-51,583,914118,611,673-55,227,127-45,780,925-55,956,000
Earnings
Aug 11, 2025

Profile

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
URL
https://ovidrx.com/
IPO date
May 05, 2017
Employees
40
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
566
44.50%
392
-73.93%
1,503
-99.28%
Cost of revenue
62,451
59,673
58,433
Unusual Expense (Income)
NOPBT
(61,885)
(59,281)
(56,930)
NOPBT Margin
Operating Taxes
(2,761)
Tax Rate
NOPAT
(61,885)
(59,281)
(54,169)
Net income
(26,433)
-49.50%
(52,339)
1.81%
(51,408)
-141.85%
Dividends
Dividend yield
Proceeds from repurchase of equity
535
180,658
BB yield
-0.24%
-137.92%
Debt
Debt current
1,336
1,246
534
Long-term debt
1,336
30,757
32,537
Deferred revenue
Other long-term liabilities
13,419
30,000
Net debt
(71,377)
(91,456)
(101,553)
Cash flow
Cash from operating activities
(55,956)
(45,781)
(55,227)
CAPEX
(71)
(40)
(1,419)
Cash from investing activities
54,594
(2,581)
(87,883)
Cash from financing activities
622
30,535
181
FCF
(60,452)
(57,874)
(69,997)
Balance
Cash
53,075
105,833
129,001
Long term investments
20,974
17,626
5,623
Excess cash
74,021
123,439
134,549
Stockholders' equity
(304,263)
(277,794)
(225,498)
Invested Capital
387,244
411,593
374,306
ROIC
ROCE
EV
Common stock shares outstanding
70,905
70,581
70,425
Price
0.93
-71.00%
3.22
73.12%
1.86
-42.06%
Market cap
66,204
-70.87%
227,270
73.50%
130,990
-40.05%
EV
(5,173)
135,814
29,438
EBITDA
(61,272)
(57,685)
(55,548)
EV/EBITDA
0.08
Interest
2,761
Interest/NOPBT